{"id":50166,"date":"2022-10-27T15:02:39","date_gmt":"2022-10-27T13:02:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/"},"modified":"2022-10-27T15:02:39","modified_gmt":"2022-10-27T13:02:39","slug":"synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/","title":{"rendered":"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh"},"content":{"rendered":"
\n

\n– Milestone marks a new opportunity for patients with severe paralysis to receive groundbreaking Stentrode device\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–Synchron<\/a>, the leading endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced enrollment in the COMMAND trial has commenced at the University of Pittsburgh (the \u201cUniversity\u201d), Pittsburgh, PA.\n<\/p>\n

<\/a><\/p>\n

\nThe COMMAND trial is an early feasibility study (EFS) funded by the National Institutes of Health (NIH), and will primarily assess safety while beginning to explore quantified efficacy measures of Synchron\u2019s Stentrode<\/a>\u2122 in patients with severe paralysis with the goal of enabling the patient to control digital devices, hands-free.\n<\/p>\n

\nThe COMMAND trial is being conducted under the first investigational device exemption (IDE) awarded by the FDA to a company assessing a permanently implanted BCI. This new site at the University marks the second approved COMMAND trial location, joining Mount Sinai in New York.\n<\/p>\n

\n\u201cToday marks an important milestone in our mission to advance technology access for the millions of people who have lost the ability to use digital devices,\u201d said Tom Oxley, MD, PhD, CEO & Founder, Synchron. \u201cWe are excited to expand the COMMAND trial with enrollment at the University as we look to advance a scalable BCI solution to market.\u201d\n<\/p>\n

\nThe Stentrode is implanted within the motor cortex of the brain via the jugular vein in a minimally-invasive endovascular procedure. Once implanted, it detects and wirelessly transmits motor intent, restoring a capability for severely paralyzed patients to control personal devices with hands-free point-and-click. The trial will assess the impact of tasks such as texting, emailing, online shopping, and telehealth services. The FDA granted Breakthrough Device designation to Synchron in August 2020 and an IDE in July 2021.\n<\/p>\n

\n\u201cSynchron\u2019s Stentrode has the potential to restore functionality to the millions of people worldwide suffering from paralysis,\u201d said Raul Nogueira, MD, FAHA, FSIN, Endowed Professor & Division Chief of Cerebrovascular Medicine, Director, UPMC Stroke Institute, Professor of Neurology & Neurosurgery at the University of Pittsburgh. \u201cGiving patients the option to receive this device without the need for open brain surgery, may open endless possibilities into the application and scalability of this promising technology.\u201d\n<\/p>\n

\n\u201cThis exciting technology may open up the possibility for patients with paralysis to use digital devices to communicate with loved ones again, and restore independence back into their lives,\u201d said David Lacomis, MD, principal investigator and Chief of Neuromuscular Division at the University of Pittsburgh. \u201cSomething as simple as surfing the web or doing online grocery shopping can seem mundane to some, but it can change the world for someone who previously had those fundamental abilities taken away.\u201d\n<\/p>\n

\nCOMMAND trial sites in New York, NY and Pittsburgh, PA are recruiting patients. Referring physicians may direct their inquiries to COMMAND@synchron.com<\/a> to be put in touch with a study coordinator. There is no guarantee of participation and principal investigators make the final determination of patient eligibility.\n<\/p>\n

\n\u200b\u200bAbout the Stentrode\u2122<\/b>\n<\/p>\n

\nSynchron\u2019s flagship technology, the Stentrode, is an endovascular brain implant designed to enable patients to wirelessly control digital devices through thought and improve functional independence. Synchron\u2019s foundational technology, a motor neuroprosthesis (MNP), or motor BCI, is implanted via the jugular vein using neurointerventional techniques commonly used to treat stroke, and does not require drilling into the skull or open brain surgery. The system is designed for patients suffering from paralysis as a result of a broad range of conditions, and aims to be user friendly and dependable for patients to use autonomously.\n<\/p>\n

\nAbout Synchron, Inc.<\/b>\n<\/p>\n

\nSynchron, an endovascular brain interface company, is a leader in implantable neural interface technology. The clinical-stage company is developing a neuroprosthesis for the treatment of paralysis and the first endovascular implantable neuromodulation therapy. Future applications include the potential to diagnose and treat conditions of the nervous system, including Parkinson\u2019s disease, epilepsy, depression, and hypertension. Synchron is headquartered in New York City with R&D facilities in Melbourne, Australia. For more information, visit www.synchron.com<\/a>. Follow us on Twitter @synchroninc<\/a>.\n<\/p>\n

\nAbout the University of Pittsburgh:<\/b> Founded in 1787, the University of Pittsburgh is an internationally renowned leader in health sciences learning and research. A top 10 recipient of NIH funding since 1998, Pitt has repeatedly been ranked as the best public university in the Northeast, per The Wall Street Journal\/Times Higher Education. Pitt consists of a campus in Pittsburgh\u2014home to 16 undergraduate, graduate and professional schools \u2014 and four regional campuses located throughout Western Pennsylvania. Pitt offers nearly 500 distinct degree programs; serves more than 33,000 students; employs more than 13,000 faculty and staff; and awards 9,000 degrees systemwide.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKimberly Ha
\n
Synchron
\n
kha@synchron.com<\/a>\n<\/p>\n

\nTyler Hubin
\n
Moxie Communications Group
\n
synchron@moxiegrouppr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Milestone marks a new opportunity for patients with severe paralysis to receive groundbreaking Stentrode device NEW YORK–(BUSINESS WIRE)–Synchron, the leading endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced enrollment in the COMMAND trial has commenced at the University of Pittsburgh (the \u201cUniversity\u201d), Pittsburgh, PA. The … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50166","6":"format-standard","7":"category-industry"},"yoast_head":"\nSynchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Milestone marks a new opportunity for patients with severe paralysis to receive groundbreaking Stentrode device NEW YORK–(BUSINESS WIRE)–Synchron, the leading endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced enrollment in the COMMAND trial has commenced at the University of Pittsburgh (the \u201cUniversity\u201d), Pittsburgh, PA. The ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T13:02:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221027005126\/en\/1615235\/21\/synchron-new-logo-featured.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh\",\"datePublished\":\"2022-10-27T13:02:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/\"},\"wordCount\":791,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221027005126\\\/en\\\/1615235\\\/21\\\/synchron-new-logo-featured.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/\",\"name\":\"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221027005126\\\/en\\\/1615235\\\/21\\\/synchron-new-logo-featured.jpg\",\"datePublished\":\"2022-10-27T13:02:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221027005126\\\/en\\\/1615235\\\/21\\\/synchron-new-logo-featured.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221027005126\\\/en\\\/1615235\\\/21\\\/synchron-new-logo-featured.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/","og_locale":"en_US","og_type":"article","og_title":"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh - Pharma Trend","og_description":"– Milestone marks a new opportunity for patients with severe paralysis to receive groundbreaking Stentrode device NEW YORK–(BUSINESS WIRE)–Synchron, the leading endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced enrollment in the COMMAND trial has commenced at the University of Pittsburgh (the \u201cUniversity\u201d), Pittsburgh, PA. The ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-27T13:02:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221027005126\/en\/1615235\/21\/synchron-new-logo-featured.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh","datePublished":"2022-10-27T13:02:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/"},"wordCount":791,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221027005126\/en\/1615235\/21\/synchron-new-logo-featured.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/","url":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/","name":"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221027005126\/en\/1615235\/21\/synchron-new-logo-featured.jpg","datePublished":"2022-10-27T13:02:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221027005126\/en\/1615235\/21\/synchron-new-logo-featured.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221027005126\/en\/1615235\/21\/synchron-new-logo-featured.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/synchron-to-begin-patient-enrollment-for-the-command-trial-of-a-brain-computer-interface-at-university-of-pittsburgh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Synchron to Begin Patient Enrollment for the COMMAND Trial of a Brain Computer Interface at University of Pittsburgh"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50166"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50166\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}